Open-label trial reveals immunogenicity of mRNA vaccines against JN.1 subvariants in adults, indicating no safety concerns.
In this ongoing, open-label, phase 3b/4 study, JN.1- and KP.2-encoding monovalent mRNA-1273 vaccines elicited robust neutralization of vaccine-matched variants (JN.1, KP.2) and cross-neutralized JN.1 subvariants circulating during the study (September 2024-November 2024; KP.3.1.1, XEC, LP.8.1) in vaccinated adults, showing reduced cross-neutralization against all subvariants tested. No safety concerns were identified.
No takes yet. Share an insight, caveat, or question.
Figueroa et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: